Patients with chronic hepatitis B, including chronic hepatitis B, hepatitis B cirrhosis (compensated or decompensated), hepatitis B-related hepatocellular carcinoma (HCC), hepatitis B with metabolic associated fatty liver disease (MAFLD), etc
Conditions
Interventions
Observation group:None
Sponsors
Xixi Hospital of Hangzhou
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Age >= 18 years old; 2.Patients diagnosed with chronic hepatitis B according to the "Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2022 Edition)" include those with chronic hepatitis B, hepatitis B-related cirrhosis (compensated or decompensated stage), hepatitis B-associated hepatocellular carcinoma (HCC), and hepatitis B combined with metabolic associated fatty liver disease (MAFLD); 3.The EMR system records are complete, including the initial diagnosis and at least one follow-up data entry; 4.The data can be traced back to 2018, and the latest follow-up data is available before 2025;
Exclusion criteria
Exclusion criteria: 1.Other major pathogenic chronic liver diseases, such as hepatitis C/D, autoimmune liver diseases (AIH, PBC, PSC), genetic metabolic liver diseases (Wilson's disease, hemochromatosis, etc.); 2.Drug induced liver injury (DILI) caused by non anti hepatitis B virus drugs is clinically determined to be related to drugs; 3.Acute hepatitis B or inactive HBsAg carriers; 4.Serious data missing or follow-up time<6 months; 5.Liver transplantation or other major interventions that may affect the natural course and treatment outcome of hepatitis B during the study period;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ALT?AST?HBV DNA?HBsAg?PLT,etc; | — |
Secondary
| Measure | Time frame |
|---|---|
| Types of antiviral drugs; | — |
Countries
China
Contacts
Public ContactZhou Jing
Xixi Hospital of Hangzhou
Outcome results
None listed